Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05746494
Other study ID # 22-630
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 21, 2022
Est. completion date May 2025

Study information

Verified date March 2024
Source The University of Texas at Dallas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders. Our goal is to determine whether stimulating the brain using transcranial Direct Current Stimulation (tDCS) can improve symptoms and daily functioning.


Description:

Paranoid ideation is a common delusion experienced by individuals with schizophrenia spectrum disorders (SSD) that negatively impacts social interactions and quality of life. Therefore, efforts to reduce paranoid thinking via neuromodulation techniques [e.g., transcranial direct current stimulation (tDCS)] are in development, with amygdala-prefrontal cortex (PFC) circuits targeted as critical components of the neural mechanisms underlying paranoia. This project aims to alleviate paranoia and improve social functioning in individuals with SSD by implementing tDCS to ventrolateral PFC. A double-blind, within-subjects, crossover design will be used to compare the effects of active vs. sham tDCS. Ecological Momentary Assessments (EMA) will also be utilized to quantify any delayed stimulation effects in daily social interactions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date May 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Age = 18-64 - Diagnosed with schizophrenia or schizoaffective disorder - Having current (in the past week) or recent (in the past month) paranoia Exclusion Criteria: - Presence or history of a pervasive developmental disorder or mental retardation as defined by IQ < 70 - Presence or history of neurological or medical disorders that contraindicate neural stimulation (e.g. presence or history of epilepsy, seizures, etc.) - Demonstrating sensory limitations, including uncorrectable visual or hearing impairments that interfere with assessment - History of electroconvulsive therapy - Lack of proficiency in English - Substance use disorder not in remission in the past 6 months - Any implanted devices such as pace maker, neurostimulator - Pregnancy

Study Design


Intervention

Device:
tDCS
active anodal tDCS and sham tDCS

Locations

Country Name City State
United States The Unversity of Texas at Dallas Richardson Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas at Dallas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by the State Social Paranoia Scale (SSPS). Participants will indicate how much they agree with each of 20 statements (e.g., "Someone was hostile towards me", "Someone was trying to isolate me") using a 5-point Likert scale (1 = do not agree, 5 = totally agree). Scores range from 20-100, and higher scores represent higher state paranoid ideation. The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by the Hostility Scale of the Personality Inventory for DSM-5 (PID-5-HS). PID-5-HS contains 10 self-report items (e.g., "I snap at people when they do little things that irritate me") assessing pathological hostility on a 4-point scale (0 = very false or often false, 3 = very true or often true), with higher total scores indicating more hostility (range = 0-30). The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by the Ambiguous Intentions Hostility Questionnaire (AIHQ). Five ambiguous scenarios will be presented to participants, and they will be asked to give reasons why each situation happened, indicate how much they think that people did this to them on purpose, how angry they are, how much they will blame others, and what they will do about it. Responses will be recorded verbatim or based on 6-point (if the behavior is on purpose) and 5-point (how angry they are, how much they will blame others) Likert scales. For the open-ended questions, hostility and aggression biases will be rated by three independent, trained raters using a 5-point Likert scale (1 = not hostile/aggressive at all, 5 = very hostile/aggressive). Inter-rater reliability will be computed by ICC among all the raters, with ICC > .80 being acceptable. The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by the Scrambled-sentences task (SST) The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by the Trustworthiness Task The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Paranoid Ideation for Active vs. Sham Stimulation Paranoid ideation will be measured by EMA (i.e., questions about feelings of paranoia in daily life). Change in daily paranoia feelings will be assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
Primary Social functioning for Active vs. Sham Stimulation Social functioning will be measured by the Birchwood Social Functioning Scale (SFS). This scale measures social adjustment based on self-reports (4- or 5-point scales), with higher total scores indicating better social functioning (range = 0-223). The assessment will be completed 30 minutes after completion of the active/sham stimulation
Primary Social functioning for Active vs. Sham Stimulation Social functioning will be measured by EMA (i.e., questions about daily interactions with others) Change in daily interactions will be assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
Primary Social functioning for Active vs. Sham Stimulation Social functioning will be measured by EMA (i.e., questions about daily experience in social interactions). Change in daily experience in social interactions will be assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
Primary Social functioning for Active vs. Sham Stimulation Social functioning will be measured by EMA (i.e., questions about daily expectations of social interactions). Change in daily expectations of social interactions will be assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A